PMCF Study of the Axonics SNM System Model 5101 (R20)
Launched by AXONICS, INC. · Jan 17, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the Axonics SNM System, which is a treatment designed to help people with conditions like urinary urge incontinence, urinary frequency, and overactive bladder. The study aims to gather more information about the safety and effectiveness of this device over a longer period of time, and it will take place after the device has already been approved for use.
To participate, you need to be at least 18 years old and have issues with overactive bladder that haven't improved with other treatments. You'll also need to be able to provide written consent and attend follow-up appointments at a clinical center. However, there are some people who won't be eligible, such as those with certain medical conditions that could interfere with the study or individuals who had a previous trial with a similar device without success. If you qualify, you can expect to have regular check-ins to assess how well the device is working for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 years or older
- • 2. Primary indication of OAB (urinary urgency incontinence (UUI) / urinary frequency (UF) who are not candidates for, or who have failed conservative treatment
- • 3. Willing and capable to provide written consent and agrees to comply with specified evaluations at clinical centers for all follow-up assessments
- Exclusion Criteria:
- • 1. Any significant medical condition that is likely to interfere with procedures, device operation, or likely to confound evaluation of endpoints (i.e., neurological conditions such as multiple sclerosis)
- • 2. Any psychiatric or personality disorder that is likely to interfere with procedures at the discretion of the participating physician; this may include poor understanding or compliance with requirements
- • 3. Previously underwent an external sacral neuromodulation SNM trial and was deemed a non-responder or was previously implanted with a sacral neuromodulation device and did not get therapeutic benefit (a non-responder)
- • 4. History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
- • 5. A female who is breastfeeding
- • 6. A female with a positive urine pregnancy test
About Axonics, Inc.
Axonics, Inc. is a leading medical technology company focused on developing innovative solutions for patients suffering from bladder and bowel dysfunction. The company specializes in advanced neuromodulation therapies, particularly through its Sacral Neuromodulation (SNM) devices, which offer safe and effective treatment options for conditions such as overactive bladder and chronic fecal incontinence. Committed to improving patient outcomes, Axonics emphasizes rigorous clinical research and development, ensuring that its products meet the highest standards of safety and efficacy. With a dedication to enhancing quality of life, Axonics is at the forefront of transforming how these common yet impactful conditions are managed.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mahreen Pakzad, MD
Principal Investigator
University College London Hospitals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported